News

Fierce Pharma2h
Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks
Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...
These Stocks Are Moving the Most Today: Tesla, Domino’s, Nvidia, Merck, Spirit AeroSystems, Meta, and More
Domino’s Pizza reports earnings, Nvidia faces stiff competition in China, and Spirit AeroSystems finalizes a deal to transfer ...
2 Must-Own Dividends At Bargain Basement Prices
Discover April's top dividend bargains! Explore high-quality blue-chip stocks like Merck & Schlumberger with strong yields, ...
Fierce Pharma23m
AACR: Merck's Keytruda prevents head and neck cancer from returning in industry-first win
Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain head and neck cancers from returning. | Ending a 20-year-plus drought, ...
Halozyme sues Merck; FDA blames cuts for Vanda delay
Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...
Devdiscourse1d
Global Health Updates: From Mergers to Measles and Medicine
The latest health-related developments include Merck's acquisition talks with SpringWorks, disbandment of a US Justice ...
The American Journal of Managed Care1d
Pembrolizumab Before, After Surgery Improves Head and Neck Cancer Outcomes: Ravindra Uppaluri, MD, PhD
Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...
Notable healthcare headlines for the week: Merck, Roche and Bausch Health in focus
Wall Street powered to its second-best weekly advance of 2025 on Friday, with the benchmark S&P 500 (SP500) jumping nearly 5% ...